Issue Date: December 7, 2015
Samsung Invests In Biologics
Samsung BioLogics will spend $730 million to build a biologics facility at its site in Songdo, South Korea. The new plant, the company’s third, will feature 180,000 L of fermentation capacity for mammalian-cell-culture-based biologics. Samsung BioLogics employs 1,000 people and expects its headcount will rise to 1,800 in 2018 when the plant comes on-line. The contract manufacturer is majority-owned by Samsung Electronics and other Samsung firms.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society